Acumen operates as a multifaceted entity that can refer either to a prominent non-profit global impact investment fund dedicated to tackling systemic poverty through patient capital or to a specialized clinical-stage biopharmaceutical corporation focused on developing neurological therapeutics for Alzheimer's disease. While the impact investment organization builds sustainable social enterprises across developing regions, the pharmaceutical firm targets toxic amyloid-beta oligomers to address neurodegenerative disorders.
Monash IVF has a pioneering history spanning over five decades, having been originally formed as a research program in 1971. The organization achieved major medical milestones early on, including recording the world's first IVF pregnancy in 1973, facilitating Australia's first IVF birth in 1980, and delivering the world's first frozen embryo birth in 1983. Over the subsequent decades, the group expanded its clinical network across Australia and international regions, eventually transitioning into a publicly traded corporate entity listed on the Australian Securities Exchange to continue its leadership in reproductive technology, specialist obstetrics, and specialized fertility care services.